166 related articles for article (PubMed ID: 30858709)
1. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Jiang Y; Zhang N; Pang H; Gao X; Zhang H
Ther Clin Risk Manag; 2019; 15():293-302. PubMed ID: 30858709
[TBL] [Abstract][Full Text] [Related]
2. Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yu X; Zhang X; Yao T; Zhang Y; Zhang Y
Front Med (Lausanne); 2021; 8():627089. PubMed ID: 33659263
[No Abstract] [Full Text] [Related]
3. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.
Sher AF; Golshani GM; Wu S
Cancer Invest; 2020 Feb; 38(2):130-138. PubMed ID: 31985314
[No Abstract] [Full Text] [Related]
4. Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.
Zhang S; Liang F; Li W; Wang Q
Eur J Cancer; 2017 Sep; 83():71-79. PubMed ID: 28719841
[TBL] [Abstract][Full Text] [Related]
5. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.
Liu K; Qin Z; Xu X; Li T; Ge Y; Mao H; Xing C
Front Oncol; 2021; 11():662731. PubMed ID: 34221977
[TBL] [Abstract][Full Text] [Related]
6. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
7. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
Yang W; Men P; Xue H; Jiang M; Luo Q
Front Oncol; 2020; 10():197. PubMed ID: 32211312
[No Abstract] [Full Text] [Related]
8. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.
Farooq MZ; Aqeel SB; Lingamaneni P; Pichardo RC; Jawed A; Khalid S; Banskota SU; Fu P; Mangla A
JAMA Netw Open; 2022 Apr; 5(4):e227722. PubMed ID: 35438755
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
10. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
12. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
13. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang T; Wang Y; Shi C; Liu X; Lv S; Wang X; Li W
Front Pharmacol; 2022; 13():955701. PubMed ID: 36133806
[No Abstract] [Full Text] [Related]
14. Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis.
Sun YM; Li W; Chen ZY; Wang Y
Front Oncol; 2021; 11():651553. PubMed ID: 34745932
[TBL] [Abstract][Full Text] [Related]
15. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qin Q; Wang J; Wang H
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.
Xavier CB; Lopes CDH; Harada G; Peres EDB; Katz A; Jardim DL
Transl Oncol; 2022 May; 19():101383. PubMed ID: 35248919
[TBL] [Abstract][Full Text] [Related]
17. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
18. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]